Document Detail

Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam.
MedLine Citation:
PMID:  7551845     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To compare the clinical and microbiological outcome of a single-dose administration of cefuroxime or combined piperacillin/tazobactam (PT) after transrectal prostatic core-biopsy (TPB) in a prospective, randomized, open-label study. PATIENTS AND METHODS: Of 111 eligible men consecutively undergoing ultrasonographically guided TPB, 56 received 1.5 g cefuroxime and 55 received 4.5 g PT intravenously 20 min before the procedure. The anterior rectal wall was cleaned with an antiseptic swab and four biopsies were taken. Urine and blood cultures were evaluated before the procedure and again after 48 h, and oral temperature and symptoms recorded for 72 h after TPB. RESULTS: A clinically successful outcome (no symptoms to indicate urinary or systemic sepsis or pyrexia > or = 37.5 degrees C after TPB) was achieved in 100 of 108 men (92.6%), of whom 51 received cefuroxime and 49 PT. Microbiological success (no bacteriuria > 10(5) organisms/mL, or bacteraemia, after TPB) was observed in 98 of 103 men (95%), of whom 48 received PT and 50 cefuroxime. Bacteriuria was present 48 h after TPB in 5% of the men. One man randomized to receive cefuroxime became bacteraemic (with Escherichia coli) and required hospital admission. Four of the five microbiological failures were caused by organisms sensitive to the administered antimicrobial agent. No anaerobic organisms were cultured. The most common adverse event recorded was transient diarrhoea, reported by 16 men receiving PT and two receiving cefuroxime. CONCLUSION: With this prophylactic regimen, there was no significant difference in outcome between the groups. Most of the organisms isolated were sensitive to the administered antimicrobial agent. Thus, further reductions in sepsis after TPB may be achieved by the administration of additional oral antimicrobial prophylaxis.
S F Brewster; A P MacGowan; J C Gingell
Related Documents :
850085 - Incidence of diarrhea and colitis associated with clindamycin therapy.
17612935 - Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients rec...
8504275 - Pentamidine aerosol for prophylaxis of pneumocystis carinii pneumonia after bmt.
17900755 - Nine-year downward trends in surgical site infection rate in southeast france (1995-2003).
17209325 - Non-traumatic paraplegia in nigerian children presenting at the university college hosp...
21804825 - Why treat apogeotropic bppvs of the horizontal canal? about 30 observations.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  British journal of urology     Volume:  76     ISSN:  0007-1331     ISO Abbreviation:  Br J Urol     Publication Date:  1995 Sep 
Date Detail:
Created Date:  1995-11-13     Completed Date:  1995-11-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  15740090R     Medline TA:  Br J Urol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  351-4     Citation Subset:  IM    
Bristol Urological Institute, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bacterial Infections / prevention & control*
Biopsy, Needle
Cefuroxime / administration & dosage
Drug Therapy, Combination / administration & dosage*
Injections, Intravenous
Penicillanic Acid / administration & dosage,  analogs & derivatives
Piperacillin / administration & dosage
Prospective Studies
Prostate / pathology*
Prostatic Neoplasms / pathology*
beta-Lactamases / administration & dosage
Reg. No./Substance:
55268-75-2/Cefuroxime; 61477-96-1/Piperacillin; 87-53-6/Penicillanic Acid; 93528-38-2/tazobactam; EC
Comment In:
Br J Urol. 1996 Apr;77(4):618-9   [PMID:  8777643 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years wit...
Next Document:  The significance of prostatic intra-epithelial neoplasia.